Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Chris Garabedian
AddedMar 31, 2024
UpdatedJun 28, 2026
Chris Garabedian

Chris Garabedian

Board Member, Landos Biopharma

CrunchbaseLinkedIn

Chris Garabedian's Career

Landos Biopharma
Landos Biopharma

Blacksburg, VA, US

Board Member· Board
Tellus Therapeutics
Tellus Therapeutics

Hillsborough, NC, US

Board Member· Board
Xontogeny
Xontogeny

Boston, MA, US

Board Member· Board
AsclepiX Therapeutics
AsclepiX Therapeutics

Baltimore, MD, US

Board Member· Board
Forge Biologics
Forge Biologics

Columbus, OH, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Chris Garabedian's Career

Landos Biopharma
Landos Biopharma
Public$70M372017Blacksburg, VA, US
Board Member· Board

Leadership at Landos Biopharma

Josep Bassaganya-RieraJosep Bassaganya-RieraBoard Member
Roger AdsettRoger AdsettBoard Member
Tim MaylebenTim MaylebenBoard Member
Tiago GiraoTiago GiraoBoard Member
Gregory OakesGregory OakesBoard Member

Similar to Landos Biopharma

Lapix TherapeuticsLapix TherapeuticsBoston, MA, USDrugs, Therapeuticsest. 2020Lapix TherapeuticsBoston, MA, US · est. 2020

Lapix Therapeutics: Enhancing immune response and drug safety through targeted therapeutic modulation.

Series A · $5.9M9
Lumos PharmaLumos PharmaAustin, TX, USPharmaceuticals, Therapeuticsest. 1999Lumos PharmaAustin, TX, US · est. 1999

Lumos Pharma: A global biopharmaceutical firm based in Austin, US, specializing in rare disease therapeutics.

Public · $53.5M29
Palisade BioPalisade BioCarlsbad, CA, USTherapeuticsest. 2001Palisade BioCarlsbad, CA, US · est. 2001

Palisade Bio, Inc.: A global biopharmaceutical firm innovating therapies for gastrointestinal complications.

Public · $55.4M12
Bond BiosciencesBond BiosciencesNew York City, NY, USPharmaceuticals, Therapeuticsest. 2016Bond BiosciencesNew York City, NY, US · est. 2016

Bond Biosciences: A private biopharma firm developing non-absorbed oral therapeutics for human diseases.

Series B · $11.8M7
Tellus Therapeutics
Tellus Therapeutics
Series B$53.5M52018Hillsborough, NC, US
Board Member· Board

Leadership at Tellus Therapeutics

Simon GregorySimon GregoryBoard Member
Eric BennerEric BennerBoard Member
Fred CalloriFred CalloriBoard Member
Jason KralicJason KralicBoard Member

Similar to Tellus Therapeutics

Telo TherapeuticsTelo TherapeuticsSan Francisco, CA, USCancer Treatmentest. 2016Telo TherapeuticsSan Francisco, CA, US · est. 2016

Telo Therapeutics: A biotech firm innovating cancer treatments by targeting cell immortality.

Series A · $4.7M6
Thelium TherapeuticsThelium TherapeuticsSan Carlos, CA, USTherapeuticsest. 2019Thelium TherapeuticsSan Carlos, CA, US · est. 2019

Thelium Therapeutics: A preclinical firm in California, innovating agents for inflammatory diseases.

Series B · $18M1
Thesan PharmaceuticalsThesan PharmaceuticalsSan Clemente, CA, USPharmaceuticals, Therapeuticsest. 2011Thesan PharmaceuticalsSan Clemente, CA, US · est. 2011

Thesan Pharmaceuticals: A preclinical biopharmaceutical firm innovating skin disorder treatments.

Series B · $65M30
TellBioTellBioBeverly, MA, USCancer Detection, Cancer Treatmentest. 2019TellBioBeverly, MA, US · est. 2019

TellBio, Inc: Revolutionizing cancer detection and treatment through proprietary CTCs technology and therapeutic platforms.

Series A · $6.5M5
Xontogeny
Xontogeny
Series A$15M362016Boston, MA, US
Board Member· Board

Leadership at Xontogeny

Adam StoneAdam StoneBoard Member
AsclepiX Therapeutics
AsclepiX Therapeutics
Series A$50M162011Baltimore, MD, US
Board Member· Board

Leadership at AsclepiX Therapeutics

Jordan GreenJordan GreenCo-Founder
Steven M. AltschulerSteven M. AltschulerBoard Member
Ben AskewBen AskewBoard Member
Kevin SlawinKevin SlawinBoard Member
Aleksander S. PopelAleksander S. PopelCo-Founder
Robert DempseyRobert DempseyCEO
Forge Biologics
Forge Biologics
Series C$330M3552020Columbus, OH, US
Board Member· Board

Leadership at Forge Biologics

Matthew HammondMatthew HammondBoard Member
Jaysson EicholtzJaysson EicholtzCo-Founder
Erandi De SilvaErandi De SilvaCo-Founder
Molly BonakdarpourMolly BonakdarpourBoard Member
Timothy J MillerTimothy J MillerCo-Founder

Chris Garabedian's Similar Executives & Operators

Achmad ZakyAchmad ZakyCo-Founder · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWillix HalimWillix HalimCEO · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakBo ZhangBo ZhangCo-Founder · DiDiWILL WEI CHENGWILL WEI CHENGBoard Member · DiDi

People Similar to Chris Garabedian

Chris ContagChris ContagCo-Founder · BioEclipse TherapeuticsJohn RiceJohn RiceCo-Founder · Triathlon Medical Venture PartnersChristopher SeamsChristopher SeamsBoard Member · XperiGrace ColónGrace ColónBoard Member · CareDxGlenn RiegerGlenn RiegerBoard Member · ClutchGregory GregoriadisGregory GregoriadisBoard Member · Xenetic Biosciences